The restoration
of balance

Stalaris™

About Stalaris

iMOD.fc

We established a discovery program to leverage our knowledge of the Resokine pathway to vary exposure and activity of the iMod domain through protein engineering. The goal of the program was to develop a potential therapeutic that we refer to as Stalaris, which would possess only the N-terminal immuno-modulatory and fibro-modulatory activities of Resokine.

Our Fc fusion experiments helped delineate how to enhance the exposure of the iMod domain of Resokine while maintaining activity and provide insights into this domain harboring immuno-modulatory activity. Experiments have indicated that Fc fusion proteins can increase exposure and maintain iMod domain activity. Our efforts in this discovery program have led to the selection of our second product candidate.

Interstitial Lung Diseases (ILDs) and the Role of Immunology

The Resokine pathway may play an important role in maintaining lung health. We believe the Resokine pathway plays a role in the regulation of tissue homeostasis with respect to immune cell invasion and residence, including in lung tissue.
Among the various forms of ILD, we have identified several that result in severe and progressive lung disease and share immune-pathophysiology features that have the potential to be impacted by our demonstrated Stalaris activities. Examples of rare pulmonary diseases with an immune component include idiopathic non-specific interstitial pneumonias, idiopathic pulmonary fibrosis, lymphocytic interstitial pneumonia, bleomycin (the chemotherapeutic agent)-induced pulmonary fibrosis, and ILD in the setting of systemic sclerosis, or scleroderma, and sarcoidosis.

IND Readiness

In IND enabling studies, the selected Stalaris molecule showed promising results in a well-established mouse model of lung inflammation and pulmonary fibrosis, induced by a chemotherapeutic agent known as bleomycin.  When given in two therapeutic doses over 21 days, Stalaris was comparable to, or outperformed approved drugs with daily dosing in reducing lung inflammation and fibrosis in the bleomycin model.

With the selection of this Stalaris molecule, we are harnessing the Resokine pathway and plan to test its potential role in lung disease and to develop Stalaris as a potential therapeutic for patients with rare pulmonary diseases with an immune component.

© 2007 - 2017   aTyr Pharma.   Legal   Privacy Policy